KD 018

Drug Profile

KD 018

Alternative Names: KD018; PHY-906

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PhytoCeutica
  • Developer Kadmon Corporation; PhytoCeutica
  • Class Chemoprotectants
  • Mechanism of Action Acetylcholinesterase modulators; Cytochrome P 450 enzyme system inhibitors; Metalloprotease inhibitors; NF-kappa B inhibitors; Opioid delta receptor antagonists; P-glycoprotein inhibitors; Tachykinin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Gastrointestinal disorders; Hepatocellular carcinoma; Pancreatic cancer

Most Recent Events

  • 28 Jul 2017 Kadmon suspends patient enrolment in a phase I/II trial for data analysis for Colorectal cancer (Adjunctive treatment, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT00730158)
  • 11 May 2015 Discontinued - Phase-I/II for Colorectal cancer (Adjunctive treatment, Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (PO)
  • 11 May 2015 Discontinued - Phase-I/II for Gastrointestinal disorders (Chemotherapy-induced) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top